Sign in to view Marc’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Marc’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
London, England, United Kingdom
Sign in to view Marc’s full profile
Marc can introduce you to 5 people at Synthesized
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
3K followers
500+ connections
Sign in to view Marc’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Marc
Marc can introduce you to 5 people at Synthesized
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Marc
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Marc’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
About
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Activity
3K followers
-
Marc Moesser shared thisExcited to lead Helical’s $10M seed round! 🧪🤖 We are at a unique point in time where biological foundation models and general language reasoning models are converging. Pharma approves ~50 drugs/year against 10,000+ known diseases. The bottleneck is throughput and cost, not lack of ideas. Bio foundation models changed what’s computationally possible, but the work between model output and scientific decision is still fragmented and irreproducible. Helical is building the orchestration platform that turns siloed AI models into integrated virtual AI labs, where biologists and ML engineers share the same data, models, and results. Congrats Rick Schneider, Mathieu Klop, Maxime Allard and the Helical team. Proud to be part of the journey with great partners at Gradient , BoxGroup , Frst , Aidan Gomez (CEO Cohere), Clem Delangue 🤗 (CEO Huggingface), Mario Götze, and working with Daniel Graf to support the team.Marc Moesser shared this$300 billion goes into pharma R&D every year. Yet more than 90% of drug candidates still fail in clinical trials. The problem isn't the science - it's the system. Biological foundation models have opened the door to a new mode of discovery, where scientists can test hypotheses computationally before committing to the wet lab. But most pharma teams stall between model output and scientific decision: fragmented workflows, one-off notebooks, predictions that can't be reproduced or defended across programs. Helical was built to close that gap. Helical was founded by Rick Schneider (Amazon, Celonis), Maxime Allard (IBM data science, PhD in reinforcement learning and robotics), and Mathieu Klop (cardiologist and genomics researcher) - three school friends who took different paths to work on the same problem. They’re building the application layer pharma was missing: a virtual AI lab that turns bio foundation models into reproducible discovery workflows, with a shared system for bench scientists and ML engineers alike. Or as Rick puts it: "The models alone don't discover drugs. The system does." Today, we're delighted to lead their $10M seed round, alongside Gradient, BoxGroup, Frst, and angels including Aidan Gomez (CEO Cohere), Clem Delangue 🤗 (CEO HuggingFace), and Mario Götze. Helical is already working with a number of top-20 pharma companies, including a public collaboration with Pfizer on predictive safety biomarkers that compresses discovery timelines from years to weeks. The funding will accelerate their expansion to additional top-20 pharma organizations. Congratulations to Rick, Maxime, Mathieu, and the whole Helical team! Read more in David Prosser's article for Forbes (link in the comments). Daniel Graf Marc Moesser
-
Marc Moesser shared thisHuge to see the ASCENT partnership announcement out between Dunia, Siemens Energy, BASF, and the Fritz-Haber-Institut der Max-Planck-Gesellschaft! 🚀 🦾 The next generation of catalysts will shape global energy policy and the energy sovereignty of Europe. It is absolutely key for us to have world-class companies like Dunia pushing the boundaries of AI-driven discovery in the material sciences.Marc Moesser shared thisDunia is joining forces with Siemens Energy, BASF, Helmholtz-Zentrum Berlin, Technische Universität Berlin, and Fritz-Haber-Institut der Max-Planck-Gesellschaft to reinvent how the world discovers next-generation catalysts! Somewhere inside every fuel molecule, every fertilizer, every chip… there’s a quiet overachiever doing the heavy lifting. Catalysts. And yet, for something that touches ~90% of chemical processes (impacting industries with a cumulative worth of $30–40 trillion dollars globally), the way in which the world has been discovering and scaling them has remained relatively unchanged for decades. Slow cycles, fragmented workflows, many dead-ends, and promising ideas that never quite manage to make the jump from lab to industrial relevance. Which is why we’re excited to announce ASCEND | Catalysis with Nanotechnology & AI now unites Dunia, Siemens Energy, BASF, HZB and FHI to turn Europe’s scientific leadership in catalysis into deployable, scalable technologies which are fast enough to matter. Dunia's part: Plugging our AI-native, autonomous lab stack into the mix to close the loop Berlin gave the world quantum mechanics and modern catalysis. Feels like a good place to start the next chapter. Full press release is in the comment section. #DuniaInnovations #AIforScience #MaterialsInnovation #AI #Catalysis #EnergyTransition #Partnership #ASCENDBerlin
-
Marc Moesser shared thisWe just published our European Dynamism report together with Sifted to celebrate redalpine's 20y anniversary and the progress of European tech. It was amazing to contribute to the report and bring our thoughts on intelligent enterprise to paper. I'm especially excited about companies that are able to push the frontier of Verifiers Law, using reinforcement learning and access to unique data to build lasting moats in AI. Read the report here: https://lnkd.in/eTxnZNpB
-
Marc Moesser shared thisAmazing to see Albatross AI CEO Kevin Kahn featured in Forbes talking about the groundbreaking results of their latest partnership with Wallapop. Albatross is leading the fundamental shift for e-commerce from stale recommenders to live event models, enabling real time predictions. The results speak for themselves, >2.5x engagement is absolutely game changing!Marc Moesser shared this>2.5x engagement lift is not incremental improvement. It's a paradigm shift. Following yesterday's announcement with Wallapop, I sat down with Forbes to discuss the broader shift in product discovery, and how we’re bringing users back in control. Back in November, we introduced a new technology paradigm. Just three months later, it’s live at scale: helping millions of users discover tens of millions of products in real time. Grateful to David Prosser for the conversation and to Forbes for the continued coverage. Full interview (Forbes) → https://lnkd.in/eV8thpP5 Wallapop announcement (Business Insider) → https://lnkd.in/eauP-qMq This is another important milestone for Albatross AI. Huge thanks to our team, to Wallapop for a truly great partnership, and to redalpine, MMC Ventures, and daphni who believed in our vision from day one. We’re just getting started.
-
Marc Moesser shared thisThe era of "backward-looking" e-commerce is over. 🚀 For a decade, discovery engines have been stuck in the past, showing you what you already bought or what someone else liked. It’s static, it’s repetitive, and it’s why 80% of shoppers are unsatisfied. Albatross AI is fundamentally changing of how we find things online. By shifting from static algorithms to Real-Time Sequential AI, they aren't just predicting what you want, they are following the "logic of your intent" as it happens. The results from their new strategic partnership with Wallapop speak for themselves: User engagement more than doubled (+119%) during initial trials. Read more here: https://lnkd.in/ex9qmvz3 At redalpine, we back the "Game Changers." Kevin Kahn, Matteo Ruffini, Johan Boissard are going beyond the limitations of traditional LLMs and build a truly intelligent discovery layer for the global internet. Seeing this tech go live with a marketplace giant like Wallapop, and measuring the massive impact of Albatross' technology in action is just a glimpse of what's to come!Marc Moesser shared thisVery happy to announce that we’ve signed a strategic partnership with Wallapop to deploy real-time AI discovery across one of Europe’s largest marketplaces. See our joint announcement → https://lnkd.in/e256_t2r This marks our first large-scale enterprise deployment of the Albatross real-time discovery feed. Following a 7-week deployment, we observed significant impact across the entire experience: +118.9% increase in user engagement +46.9% increase in purchase intentions Proud of the Albatross team for delivering this at scale, and huge thanks to the entire Wallapop team: Rodrigo Aramayo, Rob Cassedy, Flavia Neves, Joan Lozano Jardí, Adrián Romero, and everyone who made this possible. We truly value your trust and partnership!
-
Marc Moesser shared this🚀 Albatross AI is accelerating with extra $12M funding! 🚀 Huge congrats to the team Kevin Kahn, Matteo Ruffini and Johan Boissard for this milestone and for an amazing year. Since launching the company last year and our investment, Albatross moved at a speed that is staggering. Building an entire new generation of live event models, an enterprise ready platform in production, and processing billions of events, truly impressive. However what I find even more exciting is the potential of the technology itself. The ability for AI models to understand the context and events happening at the time of query is a fundamental shift. I’m excited to welcome Mina Samaan and MMC Ventures as new investors in the company, amazing foundation for Albatross to reshape AI and move it from a static, to a dynamic paradigm.Albatross Raises $12.25 Million To Build The ‘Second Pillar Of AI’Albatross Raises $12.25 Million To Build The ‘Second Pillar Of AI’
-
Marc Moesser shared thisI'll be at Slush in Helsinki next week! If you're coming as well, would love to (re)connect and chat. 🚀Marc Moesser shared thisredalpine heads to Helsinki 🇫🇮 Slush 2025 is around the corner, and we’re excited to join thousands of founders, operators, and investors gathering in Helsinki to push European tech forward. Sebastian, Marc, and Lezama will be on the ground meeting the builders shaping the next wave of AI, deeptech, and software innovation across Europe. If you’re at Slush on November 19-20, reach out to connect - we’re always keen to meet ambitious founders and fellow ecosystem partners. See you there!
-
Marc Moesser shared this28 months faster time to reach unicorn status for European deeptech than tech is a staggering statistic. You can really see the impact of enabling tech like AI accelerating deeptech startups and helping them go faster.Marc Moesser shared thisOver the last months, I’ve received so many calls from US investors and they’ve all noticed the same thing: The companies driving Europes deep tech revolution are starting to look massively undervalued while they are overperforming. In just four years: - Total investment hit ~€15 billion in 2024 almost one-third of all European venture capital -Europe’s share of global deeptech funding nearly doubled to 19% -Our share of global deeptech unicorns doubled from 4% to 8% And deeptech companies are not just creating more value, they’re doing it faster: reaching unicorn status 28 months earlier than regular tech companies. This is the compound effect of decades of scientific depth, industrial heritage, and patient capital. From biotech in Oxbridge, to robotics in Zurich, to fusion in Munich. Europe was built for the era where physics meets intelligence.
-
Marc Moesser reposted thisMarc Moesser reposted thisSo nice to see Dunia featured on the Nasdaq tower in NYC during Climate Week. I moved to NYC when I was 23 yrs old with an intense urge to prove myself and so eager to learn. It was such a formative time for me: I met incredibly talented people at International House, taught myself ML through fast.ai at night while working in Digital R&D (for emission catalysts) at BASF during the day, fell madly in love with my life partner and deeply embraced the intoxicating "can-do" mentality that I love so much about the US. This latter mentality is really what led me all the way to today. Thanks, Norrsken, let's fix the future, we can do it!! I want to see Dunia not just on Times Square but deeply embedded in the material fabric of people's everyday products. #AI4Science #DeepTech #Energy #Materials
-
Marc Moesser liked thisMarc Moesser liked thisHelical Raises $10M https://lnkd.in/eESZtkCK Your go-to for local business news! Follow citybiz Rick Schneider, Daniel Graf, Aidan Gomez, Mario Götze, Gradient, BoxGroup, redalpine, Maxime Allard, Mathieu Klop, Priyank Vyas, Ivo Inglis, Titouan Chambe, Hayden Jung, Muhammad Ali, Donagh Egan, Issac Emmanuel Goh, Dmitry Ivanov, Martina Occhetta, Simon Graf, Jonathan Mortimer, Volker Bergen, Martina Oliver Huidobro, PhD, Benoit Putzeys, Bilal M.
-
Marc Moesser liked thisMarc Moesser liked thisUK-based biotech startup Helical, founded by Rick Schneider, Maxime Allard, and Mathieu Klop, has raised $10 million in seed funding led by redalpine, with support from Gradient, BoxGroup, Frst, and several angel investors including Aidan Gomez, Clément Delangue, Ivan Zhang, and Mario Götze. The fresh capital will be used to expand deployments with pharma clients and improve Helical’s platform for faster, more reproducible drug discovery. 🔗 https://lnkd.in/dSfH6SfXUK’s biotech startup Helical raises $10M to build a virtual AI lab for drug discoveryUK’s biotech startup Helical raises $10M to build a virtual AI lab for drug discovery
-
Marc Moesser liked thisMarc Moesser liked thisHelical, a London-based virtual AI lab focused on pharmaceutical R&D, has raised €8.4 million in a Seed round to bridge the gap between computational predictions and biological decision-making. The round was led by redalpine, with participation from Gradient, BoxGroup, Frst, and angel investors including Aidan Gomez (Cohere CEO), Clement Delangue (Hugging Face CEO), and footballer Mario Götze. “The models alone don’t discover drugs. The system does,” says Rick Schneider, co-founder of Helical. “Pharma teams need a system that turns foundation models into workflows scientists can run, validate, and defend. We built Helical to make in-silico science reproducible at pharma scale, so teams can go from hypothesis to decision in days instead of months.”
-
Marc Moesser liked thisMarc Moesser liked this💥 Super excited to launch GPT-Rosalind, our first frontier model built for scientific research across biology, drug discovery, and translational medicine. The model is trained in chemistry, protein engineering, genomics and more, including built-in knowledge of relevant databases and tools researchers use. We want to make these capabilities available to scientists and researchers while maintaining strong safeguards against biological misuse. GPT-Rosalind is launching through a trusted access deployment structure for qualified customers. We're also launching a Life Sciences plugin for Codex to everyone today, which works with our mainline models as well as GPT-Rosalind. See our blog post for videos and demos: https://lnkd.in/gq4mtACW Request access to GPT-Rosalind here: https://lnkd.in/gVCUJQHe Life Sciences plugin: https://lnkd.in/gF4JqTyu
-
Marc Moesser liked thisMarc Moesser liked thisLaunching our first life sciences model today - and we are only getting started! This + Codex —> incredible time to be a researcher! https://lnkd.in/e3mx2YCpIntroducing GPT-Rosalind for life sciences researchIntroducing GPT-Rosalind for life sciences research
-
Marc Moesser liked thisMarc Moesser liked thisHelical has secured $10 million in seed funding to advance its virtual AI lab designed to transform pharmaceutical research and development. The round was led by redalpine, with participation from Gradient, BoxGroup, and Frst. Notable angel investors include Aidan Gomez, Clément Delangue, and Mario Götze. 𝗥𝗘𝗔𝗗 𝗧𝗛𝗘 𝗗𝗘𝗧𝗔𝗜𝗟𝗦 👉 https://lnkd.in/d3vaS-jK Maxime Allard Mathieu Klop Rick Schneider Titouan Chambe Ivo Inglis Hayden Jung Muhammad Ali Priyank Vyas Issac Emmanuel Goh Donagh Egan Jonathan Mortimer Martina Occhetta Dmitry Ivanov Simon Graf Volker Bergen Martina Oliver Huidobro, PhD Benoit Putzeys #Startups #Founders #FundingNews #VentureCapital #SeedFundingHelical raises $10M Seed to build AI-Powered Virtual Lab for Drug Discovery - FoundersTodayHelical raises $10M Seed to build AI-Powered Virtual Lab for Drug Discovery - FoundersToday
-
Marc Moesser liked thisMarc Moesser liked this27 years at AstraZeneca. CTO at Exscientia, leading 200+ scientists building computational platforms for AI-driven drug discovery at scale. Now Co-Founder and CEO of DaltonTx. Garry Pairaudeau joins DDIF 2026 to examine what happens when capital markets start pricing AI-designed drugs as investable and what that means for how platforms like DaltonTx get built, funded and measured. The Savoy, London · 12–13 May 2026 · ddif.ai · Invited Audience #DrugDiscovery #DDIF2026 Key voices include Alex Alderton Werngard Czechtizky Dinesh De Alwis Harsukh Parmar, MD Uwe Gottschalk Szabolcs Nagy
-
Marc Moesser liked thisMarc Moesser liked thisI’m happy to share that I’ve started a new position as a Visiting Analyst at Atomico, joining the Venture Investment Team. Looking forward to what’s ahead!
-
Marc Moesser liked thisMarc Moesser liked this𝗧𝗵𝗿𝗶𝗹𝗹𝗲𝗱 𝘁𝗼 𝘄𝗲𝗹𝗰𝗼𝗺𝗲 Proxima Fusion as a 𝗽𝗮𝗿𝘁𝗻𝗲𝗿 𝗮𝘁 𝗗𝗧𝗠·𝗘𝗻𝗲𝗿𝗴𝘆 — on 𝟮𝟬–𝟮𝟭 𝗠𝗮𝘆 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻. Few partners represent European technological sovereignty more vividly. Proxima Fusion spun out of the Max Planck Institute for Plasma Physics in 2023 with a clear mission: build the world's first commercial stellarator fusion power plant. Just this February, they signed an MoU with Bavaria, RWE, and IPP — and launched the 𝗔𝗹𝗽𝗵𝗮 𝗔𝗹𝗹𝗶𝗮𝗻𝗰𝗲, an industrial consortium of 40+ Global companies to deliver their net-energy-gain demonstrator. Fusion is no longer a future story. It's an industrial programme. At DTM26, Francesco Sciortino will attend the VIP Investor Dinner, and Lucio Milanese will take to the 𝗧𝗶𝘁𝗮𝗻𝘀 𝗼𝗳 𝗘𝘂𝗿𝗼𝗽𝗲 stage, and join the 𝗖𝗫𝗢 𝗦𝘂𝗺𝗺𝗶𝘁 alongside Federal Ministers and European Parliament members to make the case for fusion as Europe's best shot at energy market leadership. The team will be exhibiting a model of a sectional view of a stellarator, manufactured with Rolf Kind GmbH, and a radial plate on the expo floor. Many of their Alpha Alliance partners will also be there — taking the DTM stage together to show what industrial-scale collaboration on deep tech actually looks like. Working with Maria Dantz, Jakob Fidler and Antoine Letestu on this partnership has been a joy. The conversations shaping Europe's deep tech future don't happen online. 𝗧𝗵𝗲𝘆 𝗵𝗮𝗽𝗽𝗲𝗻 𝗶𝗻 𝘁𝗵𝗲 𝗿𝗼𝗼𝗺. In case you know Proxima: like all our partners, they can give you preferential access to Deep Tech Momentum. #DTM26 #DeepTech #FusionEnergy #EuropeanSovereignty #Berlin
Experience & Education
-
redalpine
********** *******
-
***********
********* ***** ********
-
******
********* ***** ********
-
********** ** ******
****** ** ********** * *** ******* ******* ******** undefined
-
******* ********
****** ****** ********** *********
View Marc’s full experience
See their title, tenure and more.
Already on LinkedIn? Sign in
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Volunteer Experience
-
Comissioner of University Politics
ETH Zürich
Education
Memberof the Biology Department Committee and Lecture Committee.
-
Biochemistry Advisory Board Member
Heidelberg University Biochemistry Center
Education
Represented the interests of all Biochemistry students on the biochemistry advisory board. Consulting the board on the implementation of a new MSc course and budget allocations.
Courses
-
Corporate Finance - Said Business School
-
-
Entrepreneurial Finance - Said Business School
-
-
Strategy & Innovation - Saïd Business School
-
Honors & Awards
-
EIT Health Translational Fellowship award
European Insitute of Technology
Winner of the Oxford competition held by EIT Health for the best pitch and commercialisation strategy of my PhD project.
Awarded a price of 5000 EUR towards R&D. -
Hong Kong Entrepreneurship Bootcamp Gold Medal
Hong Kong Baptist University
Gold medal for the best pitch of the competition
-
Industrial Partnership
Glaxo-Smith-Kline
Partnership with GSK including Mentorship, stipend top-up as well as a personal yearly research grand.
-
EPSRC PhD Scholarship
Engineering and Physical Sciences Research Council
Full scholarship from the University of Oxford and EPSRC for the entire duration of the doctoral program (4 years).
Languages
-
English
Full professional proficiency
-
German
Native or bilingual proficiency
View Marc’s full profile
-
See who you know in common
-
Get introduced
-
Contact Marc directly
Other similar profiles
-
Drago Indjic
Drago Indjic
In addition to working close to senior management at tech and alternative investment firms, I teach several electives at leading business schools, often supervising postgraduates and exploring novel research directions like biodiversity finance compliance.<br><br>Over multiple tech and business cycles, this recipe proved robust in creating exciting business opportunities. The path includes many lessons learned from bootstrapping start-ups, exits, turnarounds, acquisitions and dissolutions.<br> <br>Two decades within the FCA regulatory perimeter comprised several hedge funds, including three start-up ventues and my own fund; a multi-family office and a sovereign wealth fund. <br><br>All this began as "data science", "quant" exercise, but was the actual start at the 1st Expert Systems Conference in London (1985), or with my paper at the 1st International Neural Network Conference ICANN in Paris (1990)?<br><br>My inquisitive mindset, engaging communication style and creativity is tested daily on Twitter: @dindjic. <br><br>I still enjoy diverse business engagements, in particular early stage/pre-seed to policy work. My network is still open but please provide a credible business rationale (be patient and prepared for KYC. I am also a former AMLO).
3K followersLondon Area, United Kingdom
Explore more posts
-
Gareth Hughes, PhD, MBA
Caizio Ventures • 2K followers
Epsilogen, a biotech firm based in the UK, has taken over the US company TigaTx to form a leading entity in "pan-isotype" cancer antibodies. This merger integrates Epsilogen's proficiency in IgE antibodies with TigaTx's specialization in IgA antibodies, enabling them to choose the most suitable antibody for specific cancer types. The merged pipeline now includes Epsilogen's MOv18 IgE, which is currently in Phase 1b clinical trials for ovarian cancer, and TigaTx's EPS 401 (previously known as TIGA-001), an anti-EGFR IgA antibody anticipated to commence clinical trials next year. This collaboration aims to enhance cancer treatments by employing various antibody isotypes to engage different elements of the immune system.
1
-
Isaac TW
STELLARINT • 690 followers
📣 Barclays Highlights M&A Catalysts for 4D Molecular Therapeutics 💊 4D-150 🏢 4D Molecular Therapeutics, Inc. 🫀 Wet AMD Barclays recently initiated coverage of 4D Molecular Therapeutics, Inc. (FDMT) with an Overweight rating and a target price of $33, highlighting the potential for the company amid solid biotech fundamentals. An anticipated increase in mergers and acquisitions within the market, alongside a reduction in price sensitivity for medicines, presents strategic tailwinds for FDMT in 2026. The company, known for its innovative Therapeutic Vector Evolution platform, is actively advancing its clinical studies, including the 4FRONT Phase 3 trials for 4D-150 aimed at treating Wet Age-related Macular Degeneration (AMD) and upcoming trials for diabetic macular edema as well as developments in its cystic fibrosis program. Financially, the biotech sector's current undervaluation compared to potential upside, particularly post-M&A activity, reinforces Barclays' bullish outlook on FDMT. While their potential is noted, there is an acknowledgment of alternative high-growth sectors, specifically AI stocks, which might present more favorable risk-reward scenarios for investors. For biopharma strategists, this suggests a need to balance potential investments in innovative biotechnologies like FDMT against rapidly evolving sectors that may also capture market attention due to their strategic positioning in a shifting economic landscape. Continuous updates on FDMT’s clinical trials and market reception will be critical in assessing its investment viability as the industry dynamics unfold throughout 2026. Read full article: https://lnkd.in/gFDhhshB #ophthalmology #4D150 #4DMolecularTherapeuticsInc
1
1 Comment -
Katie Lockwood
Twin Path Ventures • 5K followers
The UK has large reserves of lead-212, a radioactive isotope and an untapped national asset with extraordinary medical potential. The UK's National Nuclear Laboratory (UKNNL) has developed a successful protocol to harvest lead-212 from recycled nuclear fuel. This secures a sustainable, domestic supply of a critical isotope for a raft of new precision cancer medicines called Targeted Alpha Therapies. Pentabind is one of the members of the consortium and will be applying its AI aptamer design platform to support the development of aptamer-based targeted alpha therapy using lead-212. Massive congratulations to Rory Ryan Phil Haynes Miguel Gonzalez Canudas, PhD and the whole team PentaBind - this is immensely exciting
23
1 Comment -
Christophe Jurczak
Quantonation • 10K followers
One of the most exciting developments in applications of #quantumcomputing I've seen this year ! In the words of Jean-Philip Piquemal "we’re already starting to use quantum-computing algorithms to generate data to enhance our models. Leveraging partnerships with quantum hardware companies, more data will continuously be added in the future. What people thought would take until 2035 is already starting to happen today.” Combining #HPC, #AI and QC is a game changer for materials and drug design, and we're barely starting to understand the potential here, with Qubit Pharmaceuticals in the lead. The second blog in the series is out: https://lnkd.in/etK3crnY and I look forward to the next ones. To read absolutely, two preprints : - A Foundation Model for Accurate Atomistic Simulations in Drug Design https://lnkd.in/e765zWc4 - Pushing the Accuracy Limit of Foundation Neural Network Models with Quantum Monte Carlo Forces and Path Integrals https://lnkd.in/eT6RYfgA Robert Marino Anouar Benali
63
1 Comment -
Kurt Buseck
Rex Capital LLC • 3K followers
Drug discovery is famously slow, costly, and high-risk. However, Eli Lilly’s new “TuneLab” platform is changing the equation — providing smaller biotech companies with access to AI-powered R&D models that reduce time and costs. What’s striking here is that the breakthrough isn’t only in science, it’s in commercialisation. By making cutting-edge AI tools accessible, smaller companies can now compete at a level once reserved for pharma giants. That’s exactly the kind of inflexion point where investors can step in and help accelerate growth. At Rex, we look for this combination: brilliant innovation paired with the need for smarter scaling. Whether it’s advanced biotech or a sustainability startup rethinking manufacturing, we help founders build the commercial foundations to match their technical vision. 📣 If you’re a founder with disruptive technology but struggling to commercialise at pace, we’d love to connect. https://lnkd.in/e-9a4EpX
1
1 Comment -
Lukas Weber
Verve Ventures • 4K followers
🧮 What if you could precisely target the “undruggable” proteins that drive cancer — using AI-first drug design? Axiom Therapeutics brings computational precision to traditional chemistry. Their machine learning-powered platform can model covalent drug interactions, enabling the identification of small molecules that bind previously untreatable cancer proteins. Why does it matter? Despite significant advances in AI-enabled drug design for known targets, traditional discovery remains slow, costly, and largely ineffective against so-called “undruggable” proteins. Axiom’s platform aims to reproduce the successes of non-covalent drug design in the covalent space - accelerating discovery and expanding the frontier of tractable targets. 🔍 Axiom’s breakthrough: ✅ AI-driven models for covalent binding modellisation ✅ Computationally-powered Lab-in-the-loop approach ✅ Unlocking undruggable targets with next-gen small molecule discovery 🔗 Discover the science behind Axiom: https://lnkd.in/d8VQdd58 🚀 Don’t miss our upcoming webinar: DEEP TECH DEEP DIVES | Verve's Health and Bio Approach in Action 📅 July 28, 2025 - 🕛 12:00PM CET 👉 Register now https://lnkd.in/drU3_vu5 #Neurotech #Epigenetics #FutureOfMedicine #Biotech #VerveVentures #AxiomTherapeutics #RettSyndrome #HealthTech #BrainScience #DeepTech
13
-
Sonal Pai
Bristol Myers Squibb • 5K followers
𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗶𝘀 𝗲𝗻𝘁𝗲𝗿𝗶𝗻𝗴 𝗮 𝗺𝗼𝗺𝗲𝗻𝘁 𝗼𝗳 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗮𝗹 𝗿𝗲𝗮𝗹𝗶𝗴𝗻𝗺𝗲𝗻𝘁. Last year I wrote about where the biotech ecosystem might be headed by 2035- new research and policy updates call for a new revamp of latest trends in the AI x bio intersection. A few highlights: 🔬 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝗶𝗻𝗴 𝗱𝗿𝘂𝗴𝘀: Multimodal models are combining biological and clinical data to create richer patient-level representations, but the debate remains on whether diffusion or autoregressive models are better suited for biological characterization. At the same time, agent-to-agent research systems like "Virtual Biotech" recently released from Stanford are beginning to orchestrate dozens of specialized biological models inside unified workflows. 🏭 𝗕𝘂𝗶𝗹𝗱𝗶𝗻𝗴 𝗱𝗿𝘂𝗴𝘀: AI and automation are moving beyond R&D and deeper into the bioprocessing and manufacturing stack. OpenAI + Ginkgo system recently designed and executed iterative protein synthesis experiments autonomously, cutting reaction costs ~40%, while Lilly's latest digital twins of manufacturing factories materially increased peptide output. Meanwhile, regulatory conversations around Bayesian trial design and the FDA's reduction of the “two-trial” approval paradigm could reshape clinical development timelines. 💊 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝗶𝗻𝗴 𝗱𝗿𝘂𝗴𝘀: Consumer health platforms are acceleratingly becoming data ecosystems. Companies like ŌURA are exponentially partnering with institutions on continuous biometrics, lab testing, and frontier LLMs to build longitudinal health profiles - pushing care closer to continuous monitoring and earlier intervention. Virtual care clinics increasingly focus at the intersection of mental and physical health, with tailwinds from CMS' new ACCESS program. Read more below 👇
67
1 Comment -
AI Insider
17K followers
Chai Discovery has closed a $130M Series B at a $1.3B valuation to scale its AI-native foundation models for drug discovery, accelerating molecular design following the launch of Chai 2. https://lnkd.in/eerDPtEK #AI #BioTech #DrugDiscovery #FoundationModels #GenerativeAI #Funding Lachy Groom OpenAI General Catalyst Oak HC/FT Menlo Ventures Thrive Capital SV Angel Yosemite Glade Brook Capital Partners LLC Emerson Collective
4
-
Dr. Yoni Goldwasser
6K followers
Biological Foundation Models (BFMs) might finally deliver on AI’s promise in drug discovery -- but capturing their full value needs a smarter playbook. It's hard for AI-for-biotech ventures to bet solely on software licensing or fully owned assets. I believe BFMs (think LLMs for biology: trained on DNA, RNA, proteins, molecules) offer a unique opportunity to blend approaches: ⏲️ Short term: sell software/services early to prove tech, earn revenue, and accelerate learning cycles. ⏳ Long term: leverage proven tech to build a proprietary drug pipeline, capturing far greater value downstream. Examples already emerging: EvolutionaryScale ($142M raised), Latent Labs (~$50M), SandboxAQ. These ventures show BFMs aren’t science fiction—they’re here, well-funded, and gaining momentum. Some of my takeaways: 👑 Proprietary datasets and model IP remain key differentiators. 📈 Pharma-scale risks require patience, but rewards scale similarly. ✌ Focus on startups executing hybrid models: immediate SaaS/services revenue + long-term pipeline ambitions. BFMs aren’t just another AI hype cycle—they could finally crack the biotech value conundrum. For some great insights read Maggie Basta's full article: https://lnkd.in/eNbbnYPS
32
2 Comments -
DaltonTx
2K followers
We're proud to be featured in the European Dynamism report by redalpine and Sifted, recognised as a #startuptowatch in Unlocking Biology. The report highlights DaltonTx as part of the next wave of AI infrastructure for drug discovery: building a third generation AI drug design platform for collaborative intelligence, based on the extensive industry expertise of our founders. As our CEO Garry Pairaudeau puts it: "I want people to view AI as an opportunity to supercharge human expertise." Europe has the scientific depth to lead in biology. We are building the platform that makes it happen. #AIdrugdiscovery #collaborativeintelligence #startuptowatch
67
1 Comment -
Sebastian Gensior
Capital for Cures AG • 8K followers
The $7.8B question for synthetic data in biotech https://lnkd.in/e7RSsSUt Generative AI in drug discovery has reached an important crossroads. In H1 2025, $7.8B was invested in synthetic data approaches, with projections for 2030 ranging from $1.5B to $20.3B. On one side, we see progress: 31 AI-discovered drugs are in human trials, and early results such as Insilico’s Rentosertib (+98.4 mL FVC in Phase IIa) highlight clinical potential. On the other, challenges remain—95% of pilots fail to scale, bias persists in synthetic patient datasets, and regulatory frameworks are still emerging. The takeaway: synthetic data is moving from concept to implementation, but the field needs robust validation, bias mitigation, and regulatory clarity before it can deliver on its promise at scale. #biotech #syntheticdata #drugdiscovery #genAI #clinicaltrials #pharma #healthtech
5
-
Christopher Hoover
Scientari LLC • 3K followers
Grounding your AI-driven discovery tools with an exhaustive compound library. Had a great discussion with Martin Razuks Ebels of MolPort at SLAS on the value of their established compound libraries. Access to a high-quality, real-world compound library can streamline the downstream phases of next-gen discovery engines. MolPort’s curated, in-stock database of 5 million screening compounds and 860K building blocks aggregates inventory from over 80 suppliers into a single, reliable source that you can access via API (or download SDF/CSV files for direct integration into your modeling pipelines. Arriving at known compounds also speeds procurement for wetlab validation. Besides training generative models, their library is also ideal for running virtual screens or sourcing building blocks for hit-to-lead campaigns. Catch up with Martin directly (martins.razuks@molport.com) or check out www.molport.com #AI #DrugDiscovery #Cheminformatics #MolPort #MachineLearning #MedicinalChemistry
14
2 Comments -
Arctoris
9K followers
The UK’s newly published AI for Science Strategy sets out a decisive vision: scientific discovery must become data-rich, automated, and engineered for scale. This aligns directly with the principles Arctoris was founded upon. At the heart of the strategy is a recognition that the next generation of AI models in drug discovery will be constrained not by compute, but by data quality. High-resolution, reproducible, metadata-complete experimental datasets are now the critical limiting input for progress. These datasets cannot be generated reliably through manual workflows. They require automation, rigorous standardisation, and an engineering-first approach to experimentation. This is the core of Arctoris’ platform. By combining robotic execution with structured data capture, we produce the precise, consistent datasets modern AI demands. Our automated infrastructure transforms experimentation into a scalable, predictable process, capable of powering advanced protein-ligand predictions, biologics developability modelling, and rapid preclinical optimisation. The UK is uniquely positioned to lead this transformation. The country benefits from world-class AI research, a sophisticated drug discovery community, and a deep-tech startup and scale-up ecosystem that understands how to industrialise science. These are strategic national assets. The government’s commitment to autonomous labs, AI-ready datasets, and mission-driven drug discovery builds on strengths that can define the UK’s competitive advantage for decades. Arctoris is proud to be part of this momentum. The alignment between policy, scientific need, and technological capability has never been stronger. This is a pivotal opportunity to build a globally leading, AI-enabled discovery industry that delivers faster innovation, stronger economic productivity, and meaningful advances in human health. We welcome the clarity and ambition shown by the Department for Science, Innovation and Technology, and we look forward to contributing to the future it envisions. #AIDrugDiscovery #AutonomousLabs #DataGeneration #EngineeringBiology #NextGenBiotech #TechBio
20
-
Eugene McDaid
8K followers
TechBio Funding Brief Dec25 – March26 Capital is flowing — but the story has shifted from “AI novelty” to deployment, integration, and translational proof. I think recent Series financings across techbio show investors backing platforms that close the loop between computation and execution: AI-native discovery engines, lab automation/“AI-ready” infrastructure, and clinically anchored precision platforms. The press consistently frames the best rounds as execution capital (scale, customers, IND readiness), not just model R&D. Quick Snapshot AI discovery & protein design Converge Bio — Series A — $25M (Jan 2026): GenAI drug discovery; press highlighted investor signal + top-tier operator angels. Galux — Series B — $29M (Feb 2026): AI protein design; framed around strengthening platform + advancing pipeline. Precision platforms (data + ML in drug development) Precede Biosciences — Series B — $63.5M equity (+$20M credit) (Jan 2026): liquid biopsy + ML for precision oncology development; coverage emphasized embedded pharma workflow value. Lab infrastructure & “model-to-lab” scaling Automata — Series C — $45M (Jan 2026): operating system for AI-ready labs; press focused on throughput + industrial validation (e.g., Danaher involvement). Medra — Series A — $52M (Dec 2025): “Physical AI scientists” (AI + robotics + closed-loop experiments); positioned as category creation for autonomous labs. Human models & reproducible biology bit.bio — Series C — $50M (Jan 2026): programmable human cell types; framed as scale-up capital for industrialising reproducible biology (and AI training data). Delivery / genetic medicine adjacency BreezeBio (GenEdit) — Series B — $60M (Feb 2026): non-viral delivery platform + pipeline; coverage leaned into “toward the clinic” execution narrative (plus rebrand signal). Clinical AI (deployment capital) Brainomix — Series C extension — +$6.5M (to $25.4M total) (Feb 2026): imaging AI; framed as commercial expansion and deployment. What the press are saying: “Integration > imagination.” Stories that win coverage are those already tied to pharma R&D workflows: decision support, reproducible lab outputs, and deployment-ready infrastructure. “The model-to-lab gap is the real bottleneck.” Automation + orchestration + data layers are increasingly portrayed as the missing substrate that makes AI claims real. “Clinical proximity is the credibility multiplier.” Rounds are framed as proof of execution: IND-enabling work, scalable operations, and measurable productivity gains — not architecture hype.
23
-
Optibrium
10K followers
Michael Kappler, PhD, PhD (Director & Head of Research Informatics at IDEAYA Biosciences) revealed how his team is delivering treatments to clinic 10-30% faster using an integrated computational platform. ✨ Key highlights: 🌠 Integrated Collaborative Drug Discovery - CDD Vault and #StarDrop alongside other tools as part of their AI/ML-driven approach 🌠Integrated our workspace for molecule design & optimisation 🌠Data-driven decision making on compound progression 🌠Significant reduction in development time and costs Watch the full recording at: https://lnkd.in/e8b7Wyev
10
1 Comment -
SynBioBeta
40K followers
From designing proteins to building AI-powered discovery platforms, Sharrol Bachas is advancing how therapeutics are created. As Co-founder and Chief Scientific Officer at Onava, Sharrol is developing a next-generation platform for therapeutic protein design, combining generative models, structural biology, protein engineering and high-throughput wet lab systems to rapidly design and optimize antibodies, peptides, and miniproteins. His work focuses on integrating AI with experimental workflows, enabling faster, iterative and human-in-the-loop design cycles. Prior to founding Onava, Sharrol led AI-driven antibody engineering at Absci and directed the integration of AI and wet lab systems for protein design at EvolutionaryScale. We’re excited to welcome him as a speaker at SynBioBeta 2026: The Programmable Biology Conference, May 4-7, 2026, at the San Jose Convention Center, California, USA. Join us in San Jose to explore how AI is reshaping the future of protein design and therapeutics. https://lnkd.in/dCn8h29G Learn More About Sharrol Bachas: https://lnkd.in/dfRAUtFc #SBB2026 #ProgrammableBiology #SynBioBeta
9
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More